Acta poloniae pharmaceutica (ACTA POL PHARM)
Current impact factor: 0.74
Impact Factor Rankings
|2015 Impact Factor ||Available summer 2016 |
|2014 Impact Factor ||0.737 |
|2013 Impact Factor ||0.693 |
|2012 Impact Factor ||0.665 |
|2011 Impact Factor ||0.663 |
|2010 Impact Factor ||0.465 |
|2009 Impact Factor ||0.347 |
Impact factor over time
|5-year impact ||0.96 |
|Cited half-life ||5.40 |
|Immediacy index ||0.07 |
|Eigenfactor ||0.00 |
|Article influence ||0.18 |
|Website || Acta poloniae pharmaceutica website |
|Other titles ||Drug research |
|ISSN ||0001-6837 |
|OCLC ||58394830 |
|Material type ||Periodical |
|Document type ||Journal / Magazine / Newspaper |
Publications in this journal
Acta poloniae pharmaceutica 01/2016;
Acta poloniae pharmaceutica 01/2016; 2.
[Show abstract] [Hide abstract]
ABSTRACT: A new series of 6,8-dibromo-2-(4-chloro-phenyl)-4-oxo-4H-quinazolin derivatives II-VI were synthesized, their chemical structures were confirmed by spectroscopic means and elemental analyses. All these compounds were tested in vitro against human breast cancer cell line (MCF-7) using resazurin reduction assay method and doxorubicin as a reference drug. Most of the tested compounds showed better activity than doxorubicin. Compound IVh was the best active one, its IC50 is 8.52 µg/ml. Molecular docking studies for the best active compounds IVb, IVc, IVf, IVh and Va were performed on the active site of estrogen receptor alpha subtype to explore the estrogen receptor binding ability of these compounds. All the docked compounds showed good fitting score energy with the active site of ERα subtype and compound IVh showed the best docking score energy(-25.3 Kcal/mol). Estrogen binding evaluation assay was performed for the docked compounds to ensure that their activity against MCF7 go through inhibition of ERα, they showed ERα inhibition at 41-85% and compound IVh was the most active one (85%).
Acta poloniae pharmaceutica 01/2016; 73(1).
Acta poloniae pharmaceutica 08/2015;
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.